Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome (ZYN2-CL-017)

被引：0
|
作者：
Tich, Nancy [1 ]
Thibodeau, Anthony [1 ]
Palumbo, Joseph [1 ]
Dobbins, Thomas [2 ]
OQuinn, Stephen [1 ]
机构：
[1] Zynerba Pharmaceut, Devon, PA USA
[2] Griesser Grp, Conshohocken, PA USA
来源：
BIOLOGICAL PSYCHIATRY | 2022年 / 91卷 / 09期
关键词：
Fragile X Syndrome; Cannabidiol; Treatment Efficacy; Safety;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P154
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 13 条
  • [1] A PIVOTAL STUDY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME [CONNECT-FX (ZYN2-CL-016)]
    Hagerman, R.
    Berry-Kravis, E.
    Budimirovic, D.
    Erickson, C.
    Heussler, H.
    Tartaglia, N.
    Cohen, J.
    Sebree, T.
    Tich, N.
    Palumbo, J.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (09) : 805 - 805
  • [2] A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    Budimirovic, Dejan
    Erickson, Craig
    Heussler, Helen
    Tartaglia, Nicole
    Cohen, Jonathan
    Dobbins, Thomas
    Merikle, Elizabeth
    Sebree, Terri
    Tich, Nancy
    Palumbo, Joseph
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S226 - S227
  • [3] A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
    Elizabeth Berry-Kravis
    Randi Hagerman
    Dejan Budimirovic
    Craig Erickson
    Helen Heussler
    Nicole Tartaglia
    Jonathan Cohen
    Flora Tassone
    Thomas Dobbins
    Elizabeth Merikle
    Terri Sebree
    Nancy Tich
    Joseph M. Palumbo
    Stephen O’Quinn
    Journal of Neurodevelopmental Disorders, 2022, 14
  • [4] A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    Budimirovic, Dejan
    Erickson, Craig
    Heussler, Helen
    Tartaglia, Nicole
    Cohen, Jonathan
    Tassone, Flora
    Dobbins, Thomas
    Merikle, Elizabeth
    Sebree, Terri
    Tich, Nancy
    Palumbo, Joseph M.
    O'Quinn, Stephen
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2022, 14 (01)
  • [5] LONGER TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030])
    Heussler, H.
    Duhig, M.
    Hurst, T.
    O'Neill, C.
    Gutterman, D.
    Palumbo, J. M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (09) : 805 - 806
  • [6] A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
    Helen Heussler
    Jonathan Cohen
    Natalie Silove
    Nancy Tich
    Marcel O. Bonn-Miller
    Wei Du
    Carol O’Neill
    Terri Sebree
    Journal of Neurodevelopmental Disorders, 2019, 11
  • [7] A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
    Heussler, Helen
    Cohen, Jonathan
    Silove, Natalie
    Tich, Nancy
    Bonn-Miller, Marcel O.
    Du, Wei
    O'Neill, Carol
    Sebree, Terri
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2019, 11 (1)
  • [8] AN OPEN-LABEL, TOLERABILITY AND EFFICACY STUDY OF ZYN002 (CANNABIDIOL) Administered As A Transdermal Gel To Children And Adolescents With 22Q11.2 Deletion Syndrome (INSPIRE)
    Heussler, H.
    Cohen, J.
    Buchanan, C.
    O'Neill, C.
    Sebree, T.
    O'Quinn, S.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2022, 66 (8-9) : 672 - 672
  • [9] AN OPEN-LABEL TRIAL ASSESSING SHORT- AND LONG-TERM TOLERABILITY AND EFFICACY OF ZYN002 (CANNABIDIOL) ADMINISTERED AS A TRANSDERMAL GEL TO CHILDREN AND ADOLESCENTS WITH 22Q11.2 DELETION SYNDROME (INSPIRE)
    Heussler, H.
    Duhig, M.
    Cohen, J.
    Buchanan, C.
    O'Neill, C.
    O'Quinn, S.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2023, 67 (09) : 808 - 809
  • [10] An Open-Label, Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
    Heusslar, Helen
    Cohen, Jonathan
    Buchanan, Caroline
    O'Neill, Carol
    O'Quinn, Stephen
    Sebree, Terri
    Siegel, Steven
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 129 - 129
12